Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care ...